Connect with us

Media OutReach

A First in the Asia-Pacific – Taiwan Leads the Launch of the Early Kidney Disease Annual Report, Opening a New Era in Advancing Kidney Care

Published

on

TAIPEI, TAIWAN – Media OutReach Newswire – 11 December 2025 – Taiwan’s chronic disease care is once again at the forefront internationally, taking new strides with the release of the Asia-Pacific’s first “Early Chronic Kidney Disease Annual Report,” jointly published by the Ministry of Health and Welfare, the National Health Research Institutes, and the Taiwan Society of Nephrology. This report not only comprehensively covers the information on various stages of chronic kidney disease but also provides timely and internationally relevant data that has garnered high attention from the Asia-Pacific medical community.

Domestic and international leaders gathered at the launch ceremony of the 2025 Early CKD Annual Report Press Conference, symbolizing the formal release of the first early kidney disease annual report in the Asia-Pacific region and showcasing Taiwan’s international leadership position in precise kidney care. From left to right are:

  • Yung-Ho Hsu, Secretary General of the Taiwan Society of Nephrology
  • Shang-Jyh Hwang, Honorary President of the Taiwan Society of Nephrology
  • Masaomi Nangaku, Immediate Past-President of the International Society of Nephrology
  • Marcello Tonelli, President of the International Society of Nephrology
  • Mai-Szu Wu, President of the Taiwan Society of Nephrology
  • Chung-Liang Shih, Minister of the Ministry of Health and Welfare
  • Ching-Fen Shen, Director General of the Health Promotion Administration, Ministry of Health and Welfare
  • Chih-Cheng Hsu, Professor at the National Health Research Institutes
  • Hyeong-Cheon Park, President Elect of the Asia Pacific Society of Nephrology
  • Rajnish Mehrotra, President of the International Society of Peritoneal Dialysis

The complete and immediate analysis aids in reversing the past trend where most patients were diagnosed at late stages and required dialysis, ushering in a new era of early detection and treatment. Minister of Health and Welfare, Chung-Liang Shih, stated at a press conference that this annual report serves as a new engine for promoting precise care, integrating complete data and risk classification indicators for Early CKD P4P(Pay for Performance) and Pre-ESRD P4P. This fills the gap in early kidney disease data and strengthens the quantitative basis for policy and clinical decision-making, facilitating early intervention and delaying disease progression. The goal is to achieve the Healthy Taiwan Policy target of reducing the standardized mortality rate for chronic diseases by one-third by 2030, and for Taiwan’s care model to become an example in the Asia-Pacific, establishing a sustainable and precise new framework for kidney care.

The early kidney disease annual report reveals several key trends. According to KDIGO risk classification, the proportion of high-risk and very high-risk patients in the P4P program has gradually decreased in recent years, reflecting a shift in treatment strategies toward early intervention and prevention. This trend not only highlights the medical team’s emphasis on the care of early-stage chronic kidney disease patients but also helps delay disease progression and reduce the incidence of later-stage complications. In terms of controlling the “three highs” (hyperglycemia, hypertension, and hyperlipidemia), data shows that approximately 80% of patients meet lipid targets and nearly 60% maintain stable blood sugar levels. However, only about 30% meet the target for blood pressure below 130/80 mmHg, indicating significant challenges remain in blood pressure control. The “three highs” are important risk factors for the progression and deterioration of chronic kidney disease, making it crucial to further improve control rates. The implementation of the P4P program has already shown preliminary results, and there are expectations for more immediate, comprehensive, and rigorous data collection and tracking, which will more fully demonstrate the long-term benefits of this care model.

Data-Driven: Taiwan’s First Early Kidney Disease Annual Report Fills Care Gaps

Professor Chih-Cheng Hsu from the National Health Research Institutes pointed out that past domestic kidney disease care has primarily focused on dialysis and end-stage disease, with limited understanding of early stages and delayed updates on data. This annual report breaks through traditional reporting frameworks and represents the first integration of complete data and risk classification indicators for Early CKD P4P and Pre-ESRD P4P. Utilizing big data for in-depth analysis, it outlines the disease progression and comorbidity trends of patients at different risk levels, successfully filling the long-term gap in early kidney disease care. He noted that grasping information on early stages of disease helps clinicians intervene earlier and delay deterioration while providing quantitative evidence for health policies to promote proactive and timely kidney care strategies, enhancing Taiwan’s international competitiveness in precise health governance.

Early CKD P4P and Pre-ESRD P4P are two phased quality-based reimbursement programs promoted by the National Health Insurance Administration, addressing key care needs for early chronic kidney disease and pre-dialysis patients, respectively. Early CKD P4P primarily targets patients in CKD stages 1-3a, aiding healthcare institutions in early identification of kidney deterioration risks through disease tracking and integrated care models, providing personalized management. Pre-ESRD P4P focuses on patients in CKD stages 3b, 4-5, enhancing control of complications, medication, and nutritional management while utilizing data feedback to support treatment decisions, aiming to delay dialysis and improve care efficiency. Both programs link the complete processes from early prevention to pre-dialysis intervention, contributing to improved overall CKD care quality and patient long-term prognosis.

Precise Kidney Care: Holistic and Continuous CKD Care as a Model for Chronic Disease

Taiwan centers its approach on “precise care,” continuously optimizing the integrated chronic kidney disease care system to implement policy blueprints in clinical practice. Director General of National Health Insurance Administration, Lian-Yu Chen, mentioned that Taiwan has progressively refined various measures, from educational programs for pre-end-stage renal disease patients to integrated care plans for early chronic kidney disease. The medical team can adjust personalized treatment strategies based on patient risk classification and clinical data, strengthening disease management and follow-up effectiveness for early-stage patients. She indicated that by integrating and providing feedback across units, care gaps could be minimized to ensure that patients receive consistent medical services across different levels of care. Director General of Health Promotion Administration, Ching-Fen Shen, remarked that grassroots health education and community health advocacy go hand in hand to enhance public awareness of kidney health. Years of efforts have significantly slowed the deterioration of early kidney disease progression, with patients participating in integrated care exhibiting a lower future risk of dialysis compared to those who do not participate, showing tangible effectiveness of the Taiwan model.

Policy Linkage and Sustainable Vision: Achieving the Healthy Taiwan Goals and Leading the New Landscape of Asia-Pacific

In response to the government’s “Healthy Taiwan” policy, Taiwan is implementing a preventive kidney care model based on the Early CKD P4P and Pre-ESRD P4P systems and the Early Kidney Disease Annual Report. President of the Taiwan Society of Nephrology, Mai-Szu Wu, stated that investing in early chronic kidney disease management not only contributes to health sustainability but also reduces waste of medical resources, achieving dual benefits of health outcomes and environmental sustainability, assisting the government in its goal to reduce chronic disease mortality by one-third by 2030.

During the Asia-Pacific Nephrology Conference (APCN) held in Taipei this year, the Asia-Pacific’s first Early Kidney Disease Annual Report was officially unveiled. President of the International Society of Nephrology, Marcello Tonelli, and Immediate Past-President , Masaomi Nangaku, along with the President Elect of the Asia Pacific Society of Nephrology Hyeong-Cheon Park and Honorary Secretary Sunita Bavanandan attended as witnesses, attracting experts from South Korea, Japan, Thailand, Malaysia, Australia, New Zealand, Singapore, Hong Kong, Mongolia, Indonesia, and the Philippines. Additionally, various important domestic academic societies, including the Taiwan Academy of Family Medicine, Taiwan Society of Cardiology, the Diabetes Association of the Republic of China (Taiwan), the Taiwan Association of Clinical Diabetes, and the Taiwan Medical Clinics Association also participated and supported the event. Minister Chung-Liang Shih expressed gratitude for the collective efforts and emphasized that this kidney annual report showcases Taiwan’s leading position in medical data integration and clinical evidence, hoping that real-time and comprehensive data analysis will once again showcase Taiwan’s precision care model to the international community, working together with other countries to create a new global framework for chronic kidney disease prevention and treatment.

Hashtag: #TaiwanSocietyofNephrology

The issuer is solely responsible for the content of this announcement.

Media OutReach

Global Wellness Forum 2026 Set for June 23 in Kuala Lumpur as Malaysia’s Nutraceutical Industry Embarks on Next-Gen Transformation

Published

on

KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 16 June 2026 – Malaysia’s wellness market is moving beyond traditional competition over ingredients, dosage, and pricing toward product-format experience, sustained use, and differentiated innovation. The Global Wellness Consumer & Product Trends Forum 2026 will hold a forum on June 23, 2026, in Kuala Lumpur. Under the theme “Defining the Next Generation of Health Industry,” the event will bring together Malaysian trade associations, leading distribution channels, and Taiwanese R&D teams to jointly explore market opportunities.

As a core component, James Pereira, general manager of MADSA, will share insights on Malaysian health industry regulations. Adrian Toh, CEO & Executive Director of R Pharmacy, will provide frontline retail channel observations regarding shifting consumer demands. Alex Liao, General Manager of Welbloom Bio-Tech, will represent Taiwan to share how format innovation effectively responds to brand differentiation, consumption experiences, and market compliance needs.

Faced with brands’ attention toward differentiated experiences, Welbloom Bio-Tech will showcase its proprietary, Halal-certified FRESH-Jelly® technology on-site, demonstrating the innovative application to make supplements more food-like. Through ingredient payload capacities, zero- or low-sugar designs, and customized flavor development, FRESH-Jelly® allows supplements to maintain functionality while becoming more enjoyable to consume regularly, providing Malaysian brands with a distinctive option beyond capsules and tablets.

With the rapid rise of Malaysia’s wellness consumer market, its mature distribution channels and exceptional potential for regional expansion are accelerating the country’s growth as a critical hub for the Southeast Asian health industry. Welbloom Bio-Tech states that this forum is a bridging platform connecting Taiwan’s manufacturing capabilities with Malaysian market insights, aiming to unlock commercially viable partnerships for both regions.

The event is organized by The PAGE, co-organized by Welbloom Bio-Tech and SEAbizs, and supported by NTBSA, MATRADE, R Pharmacy, and MADSA.

Event Information】
Time: June 23, 2026, 09:30 – 14:00
Venue: The Zenith – Connexion Conference & Event Centre, Kuala Lumpur

Hashtag: #WelbloomBioTech

The issuer is solely responsible for the content of this announcement.

About Welbloom Bio-Tech

Welbloom Bio-Tech focuses on health supplement R&D, manufacturing, and dosage form innovation. Through forward-looking market foresight and robust R&D technologies, it provides one-stop services from formulation design and flavor development to manufacturing, assisting clients in Malaysia and Singapore to build highly competitive health supplements.

To learn more, please search “Welbloom” or click the link:

Continue Reading

Media OutReach

Doing Good Index 2026: Asia’s US$753 Billion Philanthropic Potential Remains Unrealized

Published

on

In the 2026 edition of its flagship policy report the Doing Good Index, the Centre for Asian Philanthropy and Society (CAPS) finds that Asia’s capacity to deploy private capital for social good is not keeping pace with its potential.

  • Asia’s social sector is under strain: 78% of the 2,166 social delivery organizations (SDOs) surveyed report insufficient domestic funding.
  • Asia is one of the fastest-growing regions for wealth creation, yet the policies and incentives needed to channel it toward social good are not keeping pace.
  • Singapore has become the first economy to enter the “Doing Excellent” category, demonstrating what alignment across regulations, tax incentives, government partnerships and efforts to create a culture of giving can achieve.
  • 84% of Asian SDOs surveyed apply the UN Sustainable Development Goals (SDGs) in their operations, pointing to their enduring value as a shared framework for coordination and collective action beyond 2030.

HONG KONG SAR – Media OutReach Newswire – 16 June 2026 – Asia’s social needs are intensifying, and official development assistance is declining. Yet, while the region’s wealth is growing dramatically, the policies, incentives and partnerships needed to channel private capital toward social good are not keeping pace. That is a key finding of the Doing Good Index 2026, the fifth edition of CAPS’s flagship policy report, which assesses the enabling environment for private social investment across 17 Asian economies.

The report finds that while the enabling environment for private social investment is in place across much of the region, its effectiveness remains uneven. Improvements in registration processes and accountability mechanisms have been accompanied by persistent barriers, including restrictions on foreign funding, regulatory complexity, and inconsistent government engagement. In many cases, policies exist on paper but are not fully implemented in practice, limiting their impact.

At the same time, although trust in SDOs remains high across the region, broader ecosystem conditions, such as media sentiment, talent pipelines, and institutional support, are showing signs of strain. 81% of SDOs struggle to secure unrestricted funds for their work, while 73% report difficulty recruiting staff, constraining the sector’s ability to turn trust into impact.

“Asia has the wealth, the will, and in many economies, the foundations of a strong enabling environment. What is needed now is concerted, aligned effort to bring them together. The potential is enormous,” said Ruth Shapiro, Co-Founder and CEO, Centre for Asian Philanthropy and Society.

Unlocking Asia’s US$753 Billion Philanthropic Potential

Even as Asia’s wealth continues to grow, the region faces significant and intensifying challenges across climate, education and health. Official development assistance is declining, and there is increasing pressure on domestic resources at precisely the moment demand for social services is rising.

If Asian economies were to contribute just 2% of GDP to philanthropy, as the United States does, it could generate an estimated US$753 billion annually for social good. That represents 15 times the official development assistance flowing into the region, and almost half the financing needed to hit the UN’s SDGs in Asia. But realizing that potential depends on strengthening the policies, incentives and partnerships that enable private capital to flow toward social good. The Doing Good Index 2026 finds that across much of Asia, those conditions are not yet in place.

“The world has changed dramatically, and Asia can no longer rely on others to address its social challenges. The Doing Good Index 2026 shows the region has the potential to meet this moment, but only if governments and philanthropists act together to build the conditions that make it possible,” said Ronnie Chan, Chairman, Centre for Asian Philanthropy and Society.

Singapore Shows What Alignment Can Achieve
Singapore has, for the first time, entered the top “Doing Excellent” category in the Doing Good Index 2026, reflecting years of deliberate effort to build a strong culture of philanthropy and civic engagement. Clear regulations, generous tax incentives, openness to foreign funding, and close collaboration between government and the social sector have created a strong enabling environment.

Singapore’s achievement demonstrates that when regulations, fiscal policy, ecosystem conditions and procurement work in concert, the outcomes are stronger. While no two economies will follow the same path, Singapore’s experience highlights the conditions that matter, such as the active promotion and alignment of philanthropy and giving across the whole of society.

The SDGs: Falling Short but Still Relevant in Asia
In the run-up to 2030, global progress toward the SDGs has fallen short of ambition, and Asia is no exception. Yet the Doing Good Index 2026 finds that 84% of SDOs continue to apply the SDGs in their work. Further, the rise of Environmental, Social and Governance (ESG) reporting has not displaced them, because most SDOs see the two frameworks as complementary rather than competing.

As the deadline approaches, the Index points to their enduring value not as a target but as a shared framework for strategy, coordination and collective action in the years ahead.

Other Findings from the Report

  • Talent shortages persist for Asia’s social sector: more than 70% of SDOs face difficulty recruiting and retaining staff across Asia.
  • AI adoption is happening, but usage remains limited: only 13% of surveyed SDOs report using AI regularly.
  • 39% of SDOs say claiming tax benefits is difficult, suggesting administrative barriers may be limiting the impact of existing incentives for giving.

Hashtag: #CAPS #DoingGood #PrivateCapital #PublicGood #Philanthropy #Impact

The issuer is solely responsible for the content of this announcement.

About the Doing Good Index

Released biennially and now in its fifth edition, the Doing Good Index is CAPS’s flagship policy research that assesses the enabling environment for doing good in Asia: the systems, policies and practices that facilitate or constrain philanthropic giving and the deployment of this capital.

CAPS’s research team surveyed 2,166 social delivery organizations (SDOs) and conducted 132 interviews with sector experts across 17 Asian economies to provide a comparative, evidence-based view of where environments are supportive, where gaps persist, and how systems can be strengthened to better mobilize private resources for public good.

The Index looks at indicators under four sub-indexes: regulations, tax and fiscal policy, ecosystem, and government procurement, which provide an understanding of the specific measures economies have taken to catalyze philanthropic giving and promote social sector development.

Since its inception, the Index has been an essential resource for policymakers, philanthropists, and nonprofit leaders seeking to understand and improve the conditions for giving across the region.

For more information, and visit .

About the Centre for Asian Philanthropy and Society (CAPS)

Established in 2013 and working across more than 17 economies in Asia, the Centre for Asian Philanthropy and Society (CAPS) is a nonprofit organization committed to improving the quantity and quality of philanthropic and private giving throughout Asia. Our mission is to maximize private capital for public good, conducting research, advisory, convening and capacity building to engage philanthropists, foundations, family offices, corporates, government bodies, social sector organizations and experts on best practices, models, policies and strategies to facilitate private giving and social investment in the region. For more information, visit and .

Continue Reading

Media OutReach

Frost & Sullivan White Paper Names Phancy Rise vGPU a Tier 1 Leading Platform

Published

on

Rise vGPU + ModelHub Power China’s AI into the Heterogeneous Orchestration Era

HONG KONG SAR – Media OutReach Newswire – 15 June 2026 – Frost & Sullivan, a globally renowned growth consulting firm, has released its “2026 AI Infrastructure Orchestration Platform White Paper”. The report recognizes Phancy Group’s Rise vGPU as a Tier 1 Leading Platform, the highest maturity tier in heterogeneous GPU orchestration. Phancy’s ModelHub also achieved the highest Overall Score in the enterprise-grade model management platform evaluation. This marks a significant endorsement of Phancy’s technological capability in heterogeneous AI infrastructure.

According to the white paper, as large model applications scale rapidly, China’s AI industry is facing structural challenges stemming from multi-chip coexistence. These include hardware heterogeneity, fragmented software stacks, persistently low GPU utilization (generally below 30%), and rising model adaptation complexity — all of which have become major bottlenecks for enterprise-scale AI deployment.

The report highlights a fundamental shift in AI infrastructure competitiveness – moving away from “single-chip performance” toward “cluster-scale system coordination.” At this critical juncture, Phancy has positioned itself as a leader in advanced orchestration through its full-stack AI infrastructure platform, offering a proven solution to heterogeneous compute challenges and helping drive China’s AI industry from “compute accumulation” into a new era of “compute orchestration.”

Phancy Rise vGPU: Tier 1 Leading Platform

In its assessment of mainstream AI infrastructure platforms, Frost & Sullivan defined Tier 1 criteria across three core dimensions: heterogeneous support, fine-grained control, and production-grade execution. Phancy Rise vGPU meets all three standards and has been recognized as a Tier 1 Leading Platform.

Rise vGPU transforms AI infrastructure from fragmented, low-efficiency device-level management to a unified software-defined control plane. Its key technology breakthroughs include:

  • Comprehensive Heterogeneous Management: Unified onboarding and management across more than 10 mainstream GPU/NPU vendors, including NVIDIA, Ascend, Cambricon, Hygon, and others.
  • Ultra-Fine Resource Partitioning: Industry-leading sub-GPU level compute and MB-level memory granularity slicing.
  • Significant Utilization Improvement: Through safe oversubscription and time/space multiplexing, GPU utilization is increased from industry averages below 30% to 70%-90%.
  • Intelligent Precision Scheduling: Multi-dimensional scheduling algorithms based on priority, topology, load, and resource awareness to achieve optimal compute allocation.
  • Production-Grade SLA Assurance: The Deterministic Execution Layer delivers committed and auditable SLA guarantees for critical inference workloads.
  • Full Lifecycle Operability: Comprehensive monitoring, metering, and cost allocation capabilities that turn GPU resources into truly operable digital assets.

Model Hub: Highest Overall Score in Model Management Platform Evaluation

Beyond compute orchestration, the report underscores the strategic importance of enterprise-grade model management platforms. As a powerful complement to Rise vGPU, Phancy ModelHub enables enterprises to build a complete full-stack AI infrastructure — from compute to models and from resource scheduling to business delivery.

The white paper notes that Phancy ModelHub delivers leading performance in key areas such as Model & Chip Compatibility, Execution Stability & Performance, and Model-GPU Coordination & Scheduling, achieving the highest Overall Score. Through its unified model management and execution platform, ModelHub creates a seamless closed-loop process covering model onboarding, deployment optimization, inference services, and version governance — significantly lowering the barrier to model deployment and accelerating AI innovation.

Dr. Dai Wenyuan, Founder & CEO of Phancy, said: “The Frost & Sullivan white paper accurately captures the inflection point in AI infrastructure development. The recognition of Rise vGPU as a Tier 1 Leading Platform and ModelHub’s top Overall Score provide important authoritative validation of Phancy’s technology strategy and product strength. As a full-stack AI cloud service platform, Phancy believes the next wave of competitiveness in the AI industry will come from systematic improvements in compute orchestration efficiency. We will continue to focus on heterogeneous compute unified scheduling and model ecosystem operations, working closely with customers and industry partners to advance China’s AI industry from ‘compute accumulation’ to a true ‘compute orchestration’ era.”

Hashtag: #PhancyGroup

The issuer is solely responsible for the content of this announcement.

About Phancy Group

Phancy Group (6682.HK) is a leading full-stack AI cloud services platform, providing comprehensive solutions for the AI 2.0 era. Our offerings include Rise vGPU, ModelHub and SageAIOS, delivering efficient and scalable AI infrastructure with end-to-end capabilities. We provide a complete solution from heterogeneous compute resource management and optimization to the deployment of intelligent agent models. These solutions empower digital transformation across a wide range of industries, supporting our vision of building a large-scale and efficient “Token Factory.”

Guided by the mission of “AI for Everyone” and positioned as the “Navigator of AI,” Phancy Group is committed to becoming a global leader in Artificial General Intelligence.

Continue Reading

Trending